ArticleAJNR. American journal of neuroradiology2014
Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.
Article in AJNR. American journal of neuroradiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- MRI findings for differentiating benign and malignant soft tissue tumors: a systematic review-part 2: key imaging findings.Skeletal radiology · 2026Pooled it
- Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in differentiation of soft tissue sarcoma from benign lesions: a systematic review of literature.Skeletal radiology · 2024Pooled it
- A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis.Neuro-oncology · 2021Pooled it
- Imaging of non-neurogenic peripheral nerve malignancy-a case series and systematic review.Skeletal radiology · 2021Pooled it
- Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.Neurology · 2016Guideline
- Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab.Journal of neuro-oncology · 2025Trial
- MRI findings for differentiating benign and malignant soft tissue tumors: a narrative review- Part 1: diagnostic performance.Skeletal radiology · 2026Review
- Diffusion-Weighted Imaging in the Musculoskeletal System: Evolving Role in Modern Imaging Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Soft tissue reporting and data system (soft tissue-RADS): framework for radiologists specializing in imaging of musculoskeletal tumors and tumor-like lesions.Skeletal radiology · 2026Review
- Hyperenhancing paravertebral mass in an adolescent: A rare presentation of unicentric Castleman disease.Radiology case reports · 2026Article
- From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.NPJ digital medicine · 2025Article
- Review
- Article
- Review
- Article
- Society of skeletal radiology position paper - recommendations for contrast use in musculoskeletal MRI: when is non-contrast imaging enough?Skeletal radiology · 2024Article
- Chronic kidney disease with malignant peripheral nerve sheath tumor of the ureter: a case report.Frontiers in oncology · 2024Article
- Primary Pathology of the Parapharyngeal Space.Clinical neuroradiology · 2023Review
- Surgery of Schwannoma in the upper limb - sensitivity and specificity of preoperative magnetic resonance imaging and relation between tumour size and symptoms.BMC musculoskeletal disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
background and purposeDifferentiating benign from malignant peripheral nerve sheath tumors can be very challenging using conventional MR imaging. Our aim was to test the hypothesis that conventional and functional MR imaging can accurately diagnose malignancy in patients with indeterminate peripheral nerve sheath tumors. MATERIALS AND
methodsThis institutional review board-approved, Health Insurance Portability and Accountability Act-compliant study retrospectively reviewed 61 consecutive patients with 80 indeterminate peripheral nerve sheath tumors. Of these, 31 histologically proved peripheral nerve sheath tumors imaged with conventional (unenhanced T1, fluid-sensitive, contrast-enhanced T1-weighted sequences) and functional MR imaging (DWI/apparent diffusion coefficient mapping, dynamic contrast-enhanced MR imaging) were included. Two observers independently assessed anatomic (size, morphology, signal) and functional (ADC values, early arterial enhancement by dynamic contrast-enhanced MR) features to determine interobserver agreement. The accuracy of MR imaging for differentiating malignant from benign was also determined by receiver operating characteristic analysis.
resultsOf 31 peripheral nerve sheath tumors, there were 9 malignant (9%) and 22 benign ones (81%). With anatomic sequences, average tumor diameter (6.3 ± 1.8 versus 3.9 ± 2.3 mm, P = .009), ill-defined/infiltrative margins (77% versus 32%; P = .04), and the presence of peritumoral edema (66% versus 23%, P = .01) were different for malignant peripheral nerve sheath tumors and benign peripheral nerve sheath tumors. With functional sequences, minimum ADC (0.47 ± 0.32 × 10(-3) mm(2)/s versus 1.08 ± 0.26 × 10(-3) mm(2)/s; P < .0001) and the presence of early arterial enhancement (50% versus 11%; P = .03) were different for malignant peripheral nerve sheath tumors and benign peripheral nerve sheath tumors. The minimum ADC (area under receiver operating characteristic curve was 0.89; 95% confidence interval, 0.73-0.97) and the average tumor diameter (area under the curve = 0.8; 95% CI, 0.66-0.94) were accurate in differentiating malignant peripheral nerve sheath tumors from benign peripheral nerve sheath tumors. With threshold values for minimum ADC ≤ 1.0 × 10(-3) mm(2)/s and an average diameter of ≥4.2 cm, malignancy could be diagnosed with 100% sensitivity (95% CI, 66.4%-100%).
conclusionsAverage tumor diameter and minimum ADC values are potentially important parameters that may be used to distinguish malignant peripheral nerve sheath tumors from benign peripheral nerve sheath tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.